Halozyme Therapeutics | HALO - Net Income


Halozyme Therapeutics reported $-141.59M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Baxter International USD -1.13B 1.08B Dec/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
United Therapeutics USD 364.3M 25.6M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024